References
- Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA99, 10231–10233 (2002).
- Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer10, 652–660 (2010).
- Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol.63(4), 322–329 (2010).
- Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J. Proteome Res.4(4), 1123–1133 (2005).
- Wandall HH, Blixt O, Tarp MA et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res.70, 1306–1313 (2010).
- Pedersen JW, Blixt O, Bennett EP et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer128(8), 1860–1871 (2011).
- Blixt O, Cló E, Nudelman AS et al. A high-throughput O-glycopeptide discovery platform for seromic profiling. J. Proteome Res.9(10), 5250–5261 (2010).
- Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anticancer vaccines. Adv. Exp. Med. Biol.491, 369–402 (2001).
- Issaq HJ, Waybright TJ, Veenstra TD. Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis32(9), 967–975 (2011).